Outcomes	O

The	O
primary	O
outcome	O
was	O
the	O
difference	B-PrimaryOutcome
in	I-PrimaryOutcome
the	I-PrimaryOutcome
interval	I-PrimaryOutcome
from	I-PrimaryOutcome
baseline	I-PrimaryOutcome
(	I-PrimaryOutcome
initiation	I-PrimaryOutcome
of	I-PrimaryOutcome
antiviral	I-PrimaryOutcome
treatment	I-PrimaryOutcome
)	I-PrimaryOutcome
to	I-PrimaryOutcome
SARS	I-PrimaryOutcome
-	I-PrimaryOutcome
CoV	I-PrimaryOutcome
-	I-PrimaryOutcome
2	I-PrimaryOutcome
nucleic	I-PrimaryOutcome
acid	I-PrimaryOutcome
negativity	I-PrimaryOutcome
by	I-PrimaryOutcome
nasopharyngeal	I-PrimaryOutcome
swab	I-PrimaryOutcome
among	I-PrimaryOutcome
the	I-PrimaryOutcome
three	I-PrimaryOutcome
antiviral	I-PrimaryOutcome
treatment	I-PrimaryOutcome
groups	I-PrimaryOutcome
,	O
with	O
each	O
of	O
these	O
two	O
tests	O
at	O
least	O
24	O
h	O
apart	O
.	O

The	O
secondary	O
outcomes	O
included	O
the	O
differences	B-SecondaryOutcome
among	I-SecondaryOutcome
the	I-SecondaryOutcome
three	I-SecondaryOutcome
groups	I-SecondaryOutcome
in	I-SecondaryOutcome
the	I-SecondaryOutcome
proportion	I-SecondaryOutcome
of	I-SecondaryOutcome
patients	I-SecondaryOutcome
with	I-SecondaryOutcome
SARS	I-SecondaryOutcome
-	I-SecondaryOutcome
CoV	I-SecondaryOutcome
-	I-SecondaryOutcome
2	I-SecondaryOutcome
nucleic	I-SecondaryOutcome
acid	I-SecondaryOutcome
negativity	I-SecondaryOutcome
at	B-TimeFrame
day	I-TimeFrame
14	I-TimeFrame
,	O
the	O
mortality	B-SecondaryOutcome
rate	I-SecondaryOutcome
at	B-TimeFrame
day	I-TimeFrame
28	I-TimeFrame
,	O
the	O
proportion	B-SecondaryOutcome
of	I-SecondaryOutcome
patients	I-SecondaryOutcome
re	I-SecondaryOutcome
-	I-SecondaryOutcome
classified	I-SecondaryOutcome
as	I-SecondaryOutcome
severe	I-SecondaryOutcome
cases	I-SecondaryOutcome
during	I-SecondaryOutcome
the	I-SecondaryOutcome
study	I-SecondaryOutcome
period	I-SecondaryOutcome
,	O
the	O
incidence	B-SecondaryOutcome
of	I-SecondaryOutcome
adverse	I-SecondaryOutcome
events	I-SecondaryOutcome
during	I-SecondaryOutcome
the	I-SecondaryOutcome
study	I-SecondaryOutcome
period	I-SecondaryOutcome
,	O
and	O
the	O
proportion	B-SecondaryOutcome
of	I-SecondaryOutcome
therapeutic	I-SecondaryOutcome
discontinuations	I-SecondaryOutcome
due	I-SecondaryOutcome
to	I-SecondaryOutcome
adverse	I-SecondaryOutcome
events	I-SecondaryOutcome
during	I-SecondaryOutcome
the	I-SecondaryOutcome
study	I-SecondaryOutcome
period	I-SecondaryOutcome
.	O

SARS	O
-	O
CoV	O
-	O
2	O
nucleic	O
acid	O
negativity	O
was	O
defined	B-OutcomeDefinition
as	I-OutcomeDefinition
the	I-OutcomeDefinition
presence	I-OutcomeDefinition
of	I-OutcomeDefinition
negative	I-OutcomeDefinition
SARS	I-OutcomeDefinition
-	I-OutcomeDefinition
COV	I-OutcomeDefinition
-	I-OutcomeDefinition
2	I-OutcomeDefinition
results	I-OutcomeDefinition
in	I-OutcomeDefinition
at	I-OutcomeDefinition
least	I-OutcomeDefinition
two	I-OutcomeDefinition
consecutive	I-OutcomeDefinition
nasopharyngeal	I-OutcomeDefinition
swabs	I-OutcomeDefinition
by	I-OutcomeDefinition
reverse	I-OutcomeDefinition
transcriptase	I-OutcomeDefinition
polymerase	I-OutcomeDefinition
chain	I-OutcomeDefinition
reaction	I-OutcomeDefinition
(	I-OutcomeDefinition
RT	I-OutcomeDefinition
-	I-OutcomeDefinition
PCR	I-OutcomeDefinition
)	I-OutcomeDefinition
,	I-OutcomeDefinition
with	I-OutcomeDefinition
an	I-OutcomeDefinition
interval	I-OutcomeDefinition
of	I-OutcomeDefinition
at	I-OutcomeDefinition
least	I-OutcomeDefinition
24	I-OutcomeDefinition
h	I-OutcomeDefinition
between	I-OutcomeDefinition
the	I-OutcomeDefinition
two	I-OutcomeDefinition
time	I-OutcomeDefinition
points	I-OutcomeDefinition
of	I-OutcomeDefinition
swab	I-OutcomeDefinition
-	I-OutcomeDefinition
taking	I-OutcomeDefinition
.	O

Of	O
the	O
two	O
consecutive	O
negative	O
RT	O
-	O
PCR	O
test	O
results	O
,	O
the	O
first	O
negative	O
result	O
was	O
used	O
to	O
calculate	O
the	O
interval	O
between	O
baseline	O
and	O
SARS	O
-	O
COV	O
-	O
2	O
nucleic	O
acid	O
negativity	O
.	O

